As the only company in Korea with an integrated “Industry-Academia-Research-Hospital” ecosystem, CHA Biotech collaborates with CHA University, the General Research Institute, and CHA Hospitals to drive innovation from basic research through to clinical trials and commercialization.

We maintain the world’s most extensive cell library, containing cell lines that can be applied to various diseases. We have secured 84 patents in in-cell technology, positioning us as a leader in the field. Using our robust R&D capabilities, CHA Biotech is focused on developing treatments for cancer, rare diseases, and age-related conditions, addressing areas of high unmet medical need.

Our business model supports continuous R&D investment while delivering consistent growth and profitability, creating a self-sustaining cycle for clinical development.

We are expanding globally, including establishing Matica Biotechnology in Texas to lead the CDMO market for next-generation cell and gene therapies. CHA Biotech is poised to become a global hub for large-scale, high-quality cell and gene therapy production with the upcoming completion of the CGB (Cell Gene Biobank) in Pangyo’s 2nd Techno Valley by 2025.

Our vision is clear: accelerating innovation, achieving new business milestones, and transforming into a world-leading biotech company.